Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0417 + ritonavir for mild to moderate symptomatic COVID-19
ChiCTR2200062792Phase 3Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of simnotrelvir and ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Efficacy assessment. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
simnotrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200062792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062792.